Our Research Results

Since we first began more than 40 years ago, Breast Cancer Trials (BCT) has contributed to more than 1,200 peer-reviewed publications and many of these research results have changed practice in the treatment and prevention of breast cancer.

The publication of the results of clinical trials research in a scientific journal or a periodic publication:

  • Fulfils the researchers’ ethical obligations to research participants and the general community;
  • Contributes to medical knowledge so doctors can make scientifically valid assessments of the benefits and risks of a new medicine or treatment for their patients.

BCT publishes study results in accordance with the BCT Publication Policy.

The citations for all of these publications are listed below, ordered by year. To search for a citation, enter a keyword/s and click search. Enclose multiple words in quotes “” to search for an exact match. Alternatively, you can search for clinical trials in a given year or for a particular clinical trial name. 

The majority of the publications can be accessed via PubMed, other research databases or publication storage systems at a university library (if you are a student/member), or directly to the journal or publication online. Many scientific journals provide articles as “open access”; however some require a subscription.



Randomized Phase II Study of Neoadjuvant Nivolumab (N) 2 week lead-in followed by 12 weeks of concurrent N+carboplatin plus paclitaxel (CbP) vs concurrent N+CbP in Triple Negative Breast Cancer (TNBC): (BCT1902/IBCSG 61-20 Neo-N).

Zdenkowski N, Loi S, Niman S, Francis P, Baron Hay S, Fox W, Punie K, Menzies A, Angus R, Mavin C, Rennie L, Stoodley I, Mann B, Kuper-Hommel M, Regan M. SABCS 2023; LBO-03, Presentation

The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: sub-analysis of the APHINITY trial.

de Azambuja E, Agostinetto E, Samy F, Di Cosimo S, Aftimos P, Ponde N, Eiger D, Lambertini M, Cameron D, Kiermaier A, Bailey A, Viale G, Loi S, Piccart M. SABCS 2023; PS09-04, Abstract

Impact of Baseline Oestradiol and Testosterone on the Preventive Effect of Anastrozole.

Cuzick J, Chu K, Keevil B, Howell A, Bonanni B, Gareth E, Holli K, Loibl S, Zdenkowski N, Cummings S. Dowsett M. SABCS 2023; PS10-03, Abstract

Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer.

Stover D, Hlauschek D, Mayer E, Symmans W, Watson M, Barozzi I, Filipits M, Ballman K, Bellet-Ezquerra M, Balko J, Rubovsky G, Zdenkowski N, Furfsky A, Steger G, Isaacs C, Loibl S, Henao F, Regan M, Liu Y, Fesl C, O’Brien P, DeMichele A, Gnant M, Metzger O. SABCS 2023; GS03-07, Abstract

Racial and Ethnic Differences in Clinical Outcomes among North American Patients with Hormone Receptor-Positive, HER2-negative, Early Breast Cancer in the PALLAS Trial (AFT-05).

Kantor O, Fayanju O, Dueck A, Gnant M, Burstein H, Goetz M, Isaacs C, Shepherd L, Hahn O, Anderson D, Miller K, Rugo H, Traina T, Dayao Z, Clifton K, Winer E, Wolff A, Wolmark N, Lu D, O’Brien P, Scovil S, DeMichele A, Mayer E. SABCS 2023; PO3-02-05, Abstract

Clinical characterization, prognostic and predictive values of HER2-low in early breast cancer in the PALLAS trial.

Nader-Marta G, Singer C, Hlauschek D, DeMichele A, Tarantino P, Pfeiler G, Marin M, Balko J, Nowecki Z, Balic M, Brufsky A, Chan A, Morris PG, Haddad T, Loibl S, Liu Y, Solkner L, Fesl C, Mayer E, Gnant M. SABCS 2023; PO1-01-13, Abstract

Total Publications: 1301